Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Astonea Labs Ltd (544409)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544409 NSE: Pharmaceuticals & Drugs | Small Cap | Astonea Labs Share Price
₹278 5.00 (1.83%)
As on 13-Aug'26 16:59
Astonea Labs Ltd (544409)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544409 NSE: Pharmaceuticals & Drugs | Small Cap | Astonea Labs Share Price
₹278 5.00 (1.83%)
As on 13-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹292 Cr.
Current Price
₹278
52-Week Low / High
₹118 / 301
TTM EPS
₹4.3
TTM Sales
₹148 Cr.
Book Value per Share
₹54.4
P/E Ratio
64.72
Higher than its 5-year historical median
Industry PE
53.4
Price to Book (P/B)
5.11
Higher than its 5-year historical median
Price to Sales (P/S)
1.98
Higher than its 5-year historical median
EV/EBITDA
23.90
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
11.95%
Outperforms industry median
Return on Capital Employed (ROCE)
10.51%
In line with industry median
Return on Assets (ROA)
3.60%
Operating Profit Margin
9.1%
Net Profit Margin
3.06%
Gross Profit Margin
7.2%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
51.33%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-11.76%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-15.51%
Asset Quality
Promoter Holding
72.30%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹47 Cr.
Equity
₹10.5 Cr.
Face Value
₹10
All Time Low / High
₹118.00 / 301.30
Check Before You Invest
Quality
Locked
Login to view analysis.
Valuation
Locked
Login to view analysis.
Price Trend
Locked
Login to view analysis.
Is Astonea Labs Ltd a good quality company?
Astonea Labs Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Astonea Labs Ltd performance compare with that of its Peers?
Revenue growth of Astonea Labs Ltd vs industry peers?
Astonea Labs Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 5.68%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Astonea Labs Ltd?
Promoters hold 72.30% of the Astonea Labs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Astonea Labs Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of 59.84% based on the current price.
10 Year X-Ray : Login to view analysis.
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Astonea Labs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|
| ROCE % ⓘ | 5.8% | 8.4% | 17% | 17.3% | 10.5% | - |
| Value Creation Index ⓘ | -0.6 | -0.4 | 0.2 | 0.2 | -0.3 | - |
Growth Parameters ⓘ |
||||||
| Sales ⓘ | 30.1 | 67.1 | 80.2 | 97.5 | 148 | 148 |
| Sales YoY Gr. | - | 123.1% | 19.6% | 21.6% | 51.3% | - |
| Adj EPS ⓘ | 0.2 | 0.7 | 5.3 | 6.9 | 4.3 | 4.3 |
| YoY Gr. | - | 200% | 641.7% | 29.8% | -38% | - |
| BVPS (₹) ⓘ | 9.9 | 10.7 | 15.6 | 23.9 | 54.4 | 54.4 |
| Adj Net Profit ⓘ | 0.2 | 0.6 | 4.1 | 5.4 | 4.5 | 5 |
| Cash Flow from Ops. ⓘ | -4.9 | -1.1 | 7.9 | 9.3 | -13.7 | - |
| Debt/CF from Ops. ⓘ | -6 | -34.3 | 5.4 | 5.8 | -3.2 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 30.1% | 51.3% | ||||
| Adj EPS ⓘ | NA | NA | 81.4% | -38% | ||||
| BVPSⓘ | NA | NA | 71.7% | 127.9% | ||||
| Share Price | - | - | - | 62.8% | ||||
Key Financial Parameters ⓘ
| Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 2.5 | 7 | 40.6 | 35.4 | 12 | 7.9 |
| Op. Profit Mgn % ⓘ | 19.4 | 10.7 | 14.9 | 15.7 | 9.2 | NAN |
| Net Profit Mgn % ⓘ | 0.6 | 0.8 | 5.1 | 5.5 | 3.1 | 3.1 |
| Debt to Equity ⓘ | 3.9 | 4.4 | 3.6 | 2.9 | 0.8 | - |
| Working Cap Days ⓘ | 0 | 204 | 229 | 245 | 217 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 80 | 94 | 114 | 102 | 0 |
Valuation of Astonea Labs - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|
| Sales | 30 | 67 | 80 | 98 | 148 |
| Operating Expenses ⓘ + | 24 | 60 | 68 | 82 | 134 |
| Operating Profit ⓘ | 6 | 7 | 12 | 15 | 14 |
| Operating Profit Margin (%) | 19.4% | 10.6% | 14.9% | 15.7% | 9.1% |
| Other Income ⓘ + | 0 | 0 | 0 | 0 | 1 |
| Interest ⓘ | 2 | 2 | 3 | 4 | 3 |
| Depreciation ⓘ | 4 | 4 | 4 | 5 | 5 |
| Profit Before Tax ⓘ | 1 | 1 | 5 | 7 | 6 |
| Tax ⓘ | 0 | 0 | 1 | 2 | 1 |
| Profit After Tax | 0 | 1 | 4 | 5 | 5 |
| PAT Margin (%) | 0.8% | 1.0% | 5.1% | 5.5% | 3.1% |
| Adjusted EPS (₹) | 0.3 | 0.9 | 5.4 | 6.9 | 4.3 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 7 | 8 | 12 | 18 | 57 | ||||||
| Debt + | 27 | 33 | 41 | 49 | 40 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | ||||||
| Trade Payables | 14 | 18 | 23 | 26 | 40 | ||||||
| Others Liabilities ⓘ | 4 | 6 | 6 | 10 | 10 | ||||||
| Total Liabilities ⓘ | 53 | 64 | 81 | 104 | 147 | ||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 21 | 21 | 22 | 26 | 31 | ||||||
| CWIP ⓘ | 0 | 0 | 2 | 4 | 8 | ||||||
| Investments ⓘ | 0 | 0 | 0 | 0 | 6 | ||||||
| Inventories | 7 | 17 | 25 | 29 | 34 | ||||||
| Trade Receivables | 19 | 19 | 25 | 38 | 52 | ||||||
| Cash Equivalents | 0 | 0 | 0 | 0 | 0 | ||||||
| Others Assets ⓘ | 5 | 8 | 7 | 6 | 16 | ||||||
| Total Assets ⓘ | 53 | 64 | 81 | 104 | 147 | ||||||
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -5 | -1 | 8 | 9 | -14 |
| Cash Flow From Investing Activity ⓘ + | -3 | -3 | -8 | -11 | -20 |
| Cash Flow From Financing Activity ⓘ + | 8 | 4 | -0 | 2 | 34 |
| Net Cash Flow ⓘ | -0 | 0 | -1 | -0 | 0 |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 3.32 | 8.5 | 40.68 | 35.36 | 11.95 | |||||
| ROCE (%) | 5.82 | 8.42 | 16.96 | 17.31 | 10.51 | |||||
| Asset Turnover Ratio | 0.57 | 1.14 | 1.1 | 1.05 | 1.18 | |||||
| PAT to CFO Conversion(x) | N/A | -1 | 2 | 1.8 | -2.8 | |||||
| Working Capital Days | ||||||||||
| Receivable Days | 234.50 | 104.50 | 101.30 | 118.50 | 111.20 | |||||
| Inventory Days | 86.50 | 64.70 | 94.40 | 101.40 | 77.90 | |||||
| Payable Days | 273 | 116 | 131.30 | 134.80 | 123.80 | |||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Astonea Labs Ltd FAQs
The current trading price of Astonea Labs on 13-Aug-2026 16:59 is ₹278.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Aug-2026 the market cap of Astonea Labs stood at ₹292.2 Cr
The latest P/E ratio of Astonea Labs as of 12-Aug-2026 is 64.72.
The latest P/B ratio of Astonea Labs as of 12-Aug-2026 is 5.11.
The 52-week high of Astonea Labs is ₹301.3 and the 52-week low is ₹118.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Astonea Labs is ₹148 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Astonea Labs Ltd is a below average quality company.
The key valuation ratios of Astonea Labs Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Astonea Labs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Astonea Labs Ltd
Astonea Labs Limited was originally incorporated as a private limited company in the name of ‘AHU Laboratories Private Limited’ on April 11, 2017, pursuant to the provisions of the Companies Act, 2013, and was granted a certificate of incorporation dated April 11, 2017, by the Deputy Registrar of Companies, Chandigarh. Further, the name of the company was changed from ‘AHU Laboratories Private Limited’ to ‘Astonea Labs Private Limited’ pursuant to a special resolution passed in the EGM of its members held on February 14, 2019. A fresh certificate of incorporation dated February 26, 2019, was issued by the Registrar of Companies, Chandigarh. The company was converted from a private limited company to a public limited company, pursuant to a special resolution passed in the EGM of its members held on January 02, 2024, and consequently, the name of the company was changed to ‘Astonea Labs Limited’ by deletion of the word ‘private’. A fresh certificate of incorporation consequent upon conversion from a private company to a public company dated January 11, 2024, was issued by the Registrar of Companies, Chandigarh.
The company specializes in the manufacturing and marketing of a wide range of pharmaceutical and cosmetic products. These include antibiotic drugs, anti-cold medications, antihistamines, and drugs for diabetes, cardiovascular diseases, gynecological concerns, analgesics, fungal infections, and multivitamins. It also offers products for skin, tooth, and hair care, available in various forms such as gels, ointments, creams, lotions, oils, and serums. All its products adhere to the rigorous standards of the pharmaceutical and cosmetics industries. Additionally, it is involved in the trading of certain packing materials and raw materials used in pharmaceutical and cosmetic products.
The company is based in Haryana, India equipped with a state-of-the-art manufacturing facility, meticulously designed and operated in strict conformity with ISO standards. The company is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies both within India and internationally. In addition to contract manufacturing, it manufactures and markets its own products under the brands ‘Glow Up’ and ‘Regero’ in the domestic market, wherein the products under Glow Up are also available through e-commerce platforms like Amazon and Tata 1MG.
Business area of the company
The company is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies both within India and internationally.
Awards, accreditations, or recognition
- March 17, 2021: Certificate of Compliance issued by UK Global Certification and Inspection Limited for manufacturing of personal care, face, and hair care products.
- March 12, 2022: Certificate of Compliance issued by UK Global Certification and Inspection Limited for manufacturing of cream, lotion, gel, ointments, aerosol, paste, soap, tablets, soft gels, powders, capsules, liquid & extracts who meet the requirements of WHO - GMP.
- April 07, 2022: Certificate of Compliance issued by UK Global Certification and Inspection Limited for being compliant with the requirements of ISO 22716:2007 in respect of manufacturing cream, lotion, gel, ointment, aerosol, paste, soap, tablets, soft gels, powders, capsules, liquid & extracts.
- April 08, 2022: Halal Certificate issued by UK Global Certification and Inspection for manufacturing of cream, lotion, gel, ointments, aerosol, paste, soap, tablets, soft gels, powders, capsules, liquid & extracts.
- April 08, 2022: ISO 22000:2018 (Food safety management system) and ISO 9001:2015 (Quality management system) issued by SM Certification Services for manufacturing of cream, lotion, gel, ointment, aerosol, paste, soap, tablets, softgels, powders, capsules, liquid & extracts.
- April 28, 2023: Site Certificate issued by State Drugs Controller-Cum-Controlling and Licensing Authority, Haryana for maintaining good manufacturing system and being compliant with the requirements of WHO-GMP for manufacturing cream, lotion, gel, ointment, aerosol, paste, soap, tablets, softgels, powders, capsules, liquid & extracts.
- October 14, 2023: ZED Bronze Certificate issued under MSME Sustainable (ZED) Certification Scheme, for fulfilling the requirements as mentioned in the guidelines for this certification while manufacturing pharmaceuticals, medicinal chemicals, and botanical products.
- April 22, 2024: GMP Certificate issued by the State Drugs Controller, Haryana for ensuring good manufacturing practices.
- April 22, 2024: Site Certificate issued by State Drugs Controller-Cum-Controlling and Licensing Authority, Haryana for maintaining good manufacturing system at the site and being compliant with the requirements of WHO-GMP while manufacturing tablets, capsules, oral powders and other external preparations.
- May 28, 2024 ISO 9001:2015 (Quality management system) and ISO 22000:2018 (Food safety management system) issued by United Kingdom Global Accreditation for manufacturers of tablets, capsules (soft gelatin and hard gelatin) oral powders and other external preparations.
- May 28, 2024: Certificate of Compliance issued by United Kingdom Global Accreditation for being compliant with the requirements of ISO 22716:2007 (Cosmetics-good manufacturing practices) (GMP) for manufacturers the categories: - A, C, H, K & L.
- May 28, 2024: ORGANIC Certificate of Compliance issued United Kingdom Global Accreditation for manufacturers of tablets, capsules (soft gelatin and hard gelatin), oral powders and other external preparations & cosmetic categories: - A, C, H, K & L.
History and milestones
- 2017: Incorporation of the Company in the name of AHU Laboratories Private Limited and acquisition of 2.5 acres of land for setting up a manufacturing facility at VillageHaripur, Tehsil- Raipur Rani, District- Panchkula, Haryana (Manufacturing Facility).
- 2018: Construction of manufacturing facility and procurement of plant and machinery.
- 2019: Changed the name of the company from AHU Laboratories Private Limited to Astonea Labs Private Limited.
- 2019: Started production with cosmetic block at the Manufacturing Facility.
- 2020: Started export with merchant exporter.
- 2021: Started second block with pharmaceutical products such as tablet, capsules, softgel, and oral powder production at the Manufacturing Facility.
- 2022: Started direct export of the pharmaceutical products Launched the brand ‘Glowup’.
- 2023: Received certification under WHO / GMP certification scheme and Eco-cert COSMOS.
- 2024: Launched the brand ‘Regero’.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
